Ranbaxy moves production in FDA workaround; Chinese company, managers fined for substandard drugs;

> Due to issues still pending with the FDA, Ranbaxy has shifted production of its Lipitor and Aricept generics out of its Paonta Sahib and Dewas plants in India to a New Jersey facility. Article

> Simcere-controlled Jiangsu Yanshen Biological Technology has been found liable for producing substandard human-use rabies vaccine and fined $4.5 million, in addition to individual penalties imposed on members of the management team. Simcere release

> GSK has short-listed Barnard Castle, in County Durham, UK, for its new biopharmaceutical plant. Story

> The five major vaccines companies--Sanofi Pasteur, Merck, GSK, Pfizer, and Novartis--comprise an oligopoly formed by high manufacturing and distribution costs insurmountable by smaller players. Report

> Four laboratories, funded in large part by Teva and a development foundation, mark Israel's first for research, development and teaching of pharmaceutical engineering. Article

> Eli Lilly's ImClone manufacturing plant in Branchburg, NJ, home to Erbitux production and 141 jobs, will close this month. Article

> Standards devote scan attention to color management, despite an emphasis on printing industry quality for packaging contamination control. Story

> Adamis Pharma and Beximco Pharma will team to introduce four generic respiratory drug formulations in the U.S. Item

> J&J says it will continue with its acquisition of Crucell but reserves the option to renegotiate the $2.27 billion price if problems at the Dutch biotechnology company's manufacturing plant in South Korea prove worse than anticipated. Article

> Animal drugmaker Bimeda will pay a $7,000 fine and spend $59,000 on environmental upgrades after Minnesota cited the company for hazardous waste violations. Article

> Datex is offering IT services in conjunction with its FootPrint WMS software. Datex release

> Russian drug distributor Protek is implementing an IBM Power7 system for its data processing center. IBM release

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.